Abstract
INTRODUCTION
Understanding attitudes toward participation among diverse preclinical Alzheimer’s disease (AD) trial participants could yield insights to instruct future recruitment.
METHODS
Using data from the Anti-Amyloid Treatment in Asymptomatic AD (A4) Study, we examined differences among mutually exclusive racial and ethnic groups in views and perceptions of amyloid imaging (VPAI), a measure of motivations to undergo amyloid biomarker testing in the setting of preclinical AD. We used linear regression to quantify differences at baseline.
RESULTS
Compared to non-Hispanic or Latino (NH) White participants, Hispanic or Latino (3.52 points, 95% confidence interval [CI]: [2.61, 4.42]); NH Asian (2.97 points, 95% CI: [1.71, 4.22]); and NH Black participants (2.79 points, 95% CI: [1.96, 3.63]) participants demonstrated higher levels of endorsement of the VPAI items at baseline.
DISCUSSION
Differences may exist among participants from differing ethnic and racial groups in motivations to undergo biomarker testing in the setting of a preclinical AD trial.
Highlights
Representative samples in AD clinical trials are vital to result in generalizability.
We assessed motivations to undergo amyloid imaging in a preclinical AD trial.
Racial and ethnic minority groups showed higher endorsement of VPAI items.
Differences were driven by perceived risk, plan/prepare, and curiosity domains.
Few observations among racial and ethnic groups changed after biomarker disclosure.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Christina M. Magana‐Ramirez,
Gimarie Irizarry‐Martinez,
Daniel L. Gillen,
Joshua D. Grill | July 23, 2024